Thiazide diuretics alone or with β-blockers impair glucose metabolism in hypertensive patients with abdominal obesity

Hypertension

Volumn 55, Issue 1, 2010, Pages 15-17

  Manrique, Camila ^a,c   Johnson, Megan ^a,c   Sowers, James R ^a,b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; HYDROCHLOROTHIAZIDE; METOPROLOL; NEBIVOLOL; THIAZIDE DIURETIC AGENT;

ABDOMINAL OBESITY; BLOOD PRESSURE MONITORING; BODY MASS; DIABETES MELLITUS; DRUG DOSE TITRATION; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MONOTHERAPY; MUSCLE BLOOD FLOW; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; DIABETES MELLITUS; DIURETICS; DRUG THERAPY, COMBINATION; FASTING; HUMANS; HYDROCHLOROTHIAZIDE; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIPOPROTEINS, HDL; METABOLIC DISEASES; OBESITY, ABDOMINAL;

EID: 73849146478     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.142620     Document Type: Note

References (10)

1. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006; 81:1637-1638.
2. Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-207.
3. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; for the ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166:2191-2201.
4. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31:1898-1904.
5. Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P, Sowers J; for the STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab. 2009;11:177-187.
6. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK, Nilson PM. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens. 2007;25:1311-1317.
7. Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55: 61-68.
8. Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K, Johansson L, Lind L. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension. 2008;52:1030-1037.
9. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DSH; for the GEMINI investigators. Metabolic effects of carvedilol vs meto-prolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236.
10. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer /3-blockers for the management of hypertension. J Clin Hypertens. 2009; 11:369-375.